We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
Novavax (NVAX - Free Report) closed at $6.41 in the latest trading session, marking a +1.75% move from the prior day. The stock's performance was ahead of the S&P 500's daily loss of 0.22%. On the other hand, the Dow registered a gain of 0.08%, and the technology-centric Nasdaq decreased by 0.51%.
Prior to today's trading, shares of the vaccine maker had lost 13.58% lagged the Medical sector's loss of 0% and the S&P 500's gain of 0.45%.
The upcoming earnings release of Novavax will be of great interest to investors. The company is predicted to post an EPS of -$0.12, indicating a 112.12% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $130.5 million, down 68.59% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $2.03 per share and revenue of $942.33 million, which would represent changes of +265.04% and +38.14%, respectively, from the prior year.
Any recent changes to analyst estimates for Novavax should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 38.61% rise in the Zacks Consensus EPS estimate. Currently, Novavax is carrying a Zacks Rank of #3 (Hold).
Looking at valuation, Novavax is presently trading at a Forward P/E ratio of 3.11. For comparison, its industry has an average Forward P/E of 19.86, which means Novavax is trading at a discount to the group.
We can also see that NVAX currently has a PEG ratio of 0.07. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.37.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 87, finds itself in the top 36% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note
Novavax (NVAX - Free Report) closed at $6.41 in the latest trading session, marking a +1.75% move from the prior day. The stock's performance was ahead of the S&P 500's daily loss of 0.22%. On the other hand, the Dow registered a gain of 0.08%, and the technology-centric Nasdaq decreased by 0.51%.
Prior to today's trading, shares of the vaccine maker had lost 13.58% lagged the Medical sector's loss of 0% and the S&P 500's gain of 0.45%.
The upcoming earnings release of Novavax will be of great interest to investors. The company is predicted to post an EPS of -$0.12, indicating a 112.12% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $130.5 million, down 68.59% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $2.03 per share and revenue of $942.33 million, which would represent changes of +265.04% and +38.14%, respectively, from the prior year.
Any recent changes to analyst estimates for Novavax should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 38.61% rise in the Zacks Consensus EPS estimate. Currently, Novavax is carrying a Zacks Rank of #3 (Hold).
Looking at valuation, Novavax is presently trading at a Forward P/E ratio of 3.11. For comparison, its industry has an average Forward P/E of 19.86, which means Novavax is trading at a discount to the group.
We can also see that NVAX currently has a PEG ratio of 0.07. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.37.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 87, finds itself in the top 36% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.